Skip to main content
Signal8

ABBOTT LABORATORIES (ABT)

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Sector: Pharmaceutical Preparations

Industry: Medical - Devices

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABTHealthcare
+1.16%$103.70
AH Close$103.50-0.19%vs close
Mkt Cap$179.44B
Float1.72B
O/S1.73B
Inst Own77.3%
SI0.8%
Div Yield2.43%
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$179.44B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership77.26%

based on 1.73B shares outstanding

SectorHealthcare
IndustryMedical - Devices
ExchangeNYSE
CountryUSUS
IPO Date-
Shares Outstanding1.73B
Float1.72B
Company Overview

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions.

The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents.

Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A.

Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments.

It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Leadership

Robert B. Ford

Chairman, Pres & Chief Executive Officer

Robert J. Alpern, M.D.

Elizabeth Cushman

Executive Vice President, General Counsel & Secretary

Lisa D. Earnhardt

Executive Vice President & Group President of Medical Devices

Employees

115K+

Country

US

Sector

Healthcare

Website

abbott.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets available
Ratings Distribution
BUY
31
HOLD
10
SELL
0
TOTAL41
Insider Trading
InsiderTypeShares
Gonzalez Patricia Paola profile photoGonzalez Patricia PaolaGrant/Award333
Conroy Kevin T profile photoConroy Kevin TGrant/Award318
Roman Michael F profile photoRoman Michael FGrant/Award381
Stratton John G profile photoStratton John GGrant/Award397
Ahuja Nita profile photoAhuja NitaGrant/Award318
Conroy Kevin T profile photoConroy Kevin TAutomatic Sell52.5K
Shareholders
77.3%
Institutional
(3022)
0.5%
Insiderⓘ
(26)
0.0%
5%+ Owners
(0)
22.3%
Unattributed (incl. retail)ⓘ
Institutional77.3%
Insider0.5%
Unattributed (incl. retail)22.3%
Sources: 13F, Form 4, 13D/13GO/S: 1.7B · checked 25 Oct 2026 · market-data provider
Insiders & Institutional Holders
52-Week Range
$81.97$135.45
$103.70(41st percentile)
Volume
Average Daily Volume10.19M
10.30M today vs 10.19M avg(+1%)

30d Avg

10.19M

60d Avg

9.47M

90d Avg

9.00M

Earnings
Dividend History
TTM Yield
2.43%
Paid quarterly
Annual (LTM)
$2.52
Latest
$0.6300
Oct 15, 26
5Y Growth
+6.96%
per year
Compliance Status
Loading compliance data...